c-MYC 基因表达在血液系统恶性肿瘤中的诊断和预后价值。

Diagnostic and prognostic value of c-MYC gene expression in hematological malignancies.

机构信息

Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science, University of Calabar, Nigeria.

Department of Medical Laboratory Science, Faculty of Basic Medical Sciences, Arthur Jarvis University, Akpabuyo, Nigeria.

出版信息

Afr Health Sci. 2023 Jun;23(2):265-273. doi: 10.4314/ahs.v23i2.30.

DOI:10.4314/ahs.v23i2.30

PMID:38223598

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10782349/

Abstract

INTRODUCTION

c-MYC plays vital role in regulation of cell proliferation and has been associated with tumorigenesis. This study is aimed at assessing diagnostic and prognostic value of plasma c-MYC expression to aid in early diagnosis and prognosis of hematological malignancies.

METHODS

Plasma c-MYC expression was determined by quantitative real time PCR using EVA Green chemistry and cluster of differentiation markers performed via immunocytochemistry.

RESULT

Plasma c-MYC was higher in subject with hematological malignancies (8.8 ± 1.1) when compared with apparently healthy controls (4.5 ± 0.5). A screening cut-off c-MYC ratio value of 9.42 with sensitivity and specificity of 65.5% and 100% respectively were obtained using receiver operator characteristic curve analysis. Plasma c-MYC was found to have no prognostic value using Kaplan-Meier analysis.

CONCLUSION

Plasma c-MYC ratio showed promising screening/diagnostic value for hematological malignancies.

摘要

简介

c-MYC 在细胞增殖的调控中起着至关重要的作用，并且与肿瘤发生有关。本研究旨在评估血浆 c-MYC 表达的诊断和预后价值，以帮助早期诊断和预测血液系统恶性肿瘤。

方法

使用 Eva Green 化学和免疫细胞化学进行的定量实时 PCR 测定了血浆 c-MYC 的表达，并通过免疫细胞化学测定了分化标记物。

结果

与明显健康的对照组（4.5 ± 0.5）相比，患有血液系统恶性肿瘤的患者（8.8 ± 1.1）的血浆 c-MYC 更高。使用接收器操作特征曲线分析获得了筛选截止值 c-MYC 比值为 9.42，灵敏度和特异性分别为 65.5%和 100%。通过 Kaplan-Meier 分析发现，血浆 c-MYC 无预后价值。